D
Dominik Wernic
Researcher at Boehringer Ingelheim
Publications - 45
Citations - 2753
Dominik Wernic is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Protease & Enzyme inhibitor. The author has an hindex of 18, co-authored 44 publications receiving 2639 citations.
Papers
More filters
Journal ArticleDOI
Cleavage of Cohesin by the CD Clan Protease Separin Triggers Anaphase in Yeast
TL;DR: It is shown here that separin is a cysteine protease related to caspases that alone can cleave Sccl in vitro and depends on a conserved protein called separin for sister chromatid separation.
Patent
Hepatitis C inhibitor tri-peptides
Montse Llinas-Brunet,Murray D. Bailey,Dale R. Cameron,Ghiro Elise,Nathalie Goudreau,Marc-André Poupart,Jean Rancourt,Youla S. Tsantrizos,Anne-Marie Faucher,Teddy Halmos,Dominik Wernic +10 more
TL;DR: In this article, a compound of formula (I) is defined as an acyl derivative of formula R4-O-C(O)-; a carboxyl of the same type of compound; a thioamide of the compound.
Journal ArticleDOI
Regulation of Human Separase by Securin Binding and Autocleavage
TL;DR: The results suggest that separase is required for sister chromatid separation during mitosis in human cells and indicate that securin inhibits separase by blocking the access of substrates to the active site of separase.
Journal ArticleDOI
Peptide-based inhibitors of the hepatitis C virus serine protease
Montse Llinas-Brunet,Murray D. Bailey,Gulrez Fazal,Sylvie Goulet,Ted Halmos,Steven R. LaPlante,Roger Maurice,Martin Poirier,Marc-André Poupart,Diane Thibeault,Dominik Wernic,Daniel Lamarre +11 more
TL;DR: Structural-activity studies on Ac-DDIVPC-OH revealed that side chains of the P4, P3 and P1 residues contribute the most to binding and that the introduction of a D-amino acid at the P5 position improves potency considerably.
Patent
Hepatitis c inhibitor peptides
Montse Llinas-Brunet,Marc-André Poupart,Jean Rancourt,Bruno Simoneau,Youla S. Tsantrizos,Dominik Wernic +5 more
TL;DR: In this article, the authors present a compound of formula (I) active against the hepatitis C virus, where when Q is CH2, a is 0, b is 0 and B is an amide derivative, then Q is N-Y, then Z is oxo or thioxo.